Jay Flatley to Assume Role of Executive Chairman of the Board of Directors of Illumina; Francis deSouza Appointed President and CEO

Francis deSouza of Illumina (Photo: Business Wire)

SAN DIEGO--()--Illumina, Inc. (NASDAQ: ILMN) today announced that Jay Flatley, current Chairman and CEO, will assume the role of Executive Chairman of the Board of Directors on July 5, 2016. Francis deSouza, currently President, will be appointed President and Chief Executive Officer on the same date and will continue to serve on the Illumina Board of Directors.

Jay joined Illumina in 1999 as President and CEO. He has grown the company from $500K in annual revenue to over $2.2 billion in 2015, both organically and through pivotal acquisitions that transformed Illumina into the leading global provider of next-generation sequencing solutions.

Blaine Bowman, Illumina’s Lead Independent Director, stated, “The Board would like to thank Jay for his dedication to the company as CEO for the last 17 years. He deserves incredible recognition for what he has accomplished in the role, and we are very pleased that he will continue to actively serve the company as Executive Chairman.”

“The time is right for Francis to become Illumina’s next President and CEO,” stated Jay Flatley, Chairman and CEO. “Francis is an exceptional leader, with a demonstrated track record of leading large organizations and implementing complex growth strategies. I look forward to partnering with him in his new role to continue the company’s strong legacy of innovation and execution.”

Francis joined Illumina in 2013 as President, working closely with Jay, the Board of Directors and the management team in setting the company’s strategic direction and leading the product development, commercial and manufacturing organizations. He has significantly influenced the performance of the company, been instrumental in Illumina’s evolution into the clinical markets and successfully executed on multiple major initiatives, including launching the HiSeq 4000 and the recent introduction of MiniSeq. As President and CEO he will assume additional leadership responsibility for the G&A and Research organizations, headed by Marc Stapley and Mostafa Ronaghi respectively.

“I joined Illumina because I believe in the enormous potential of our mission to improve human health by unlocking the power of the genome,” commented Francis deSouza, President. “Today, having witnessed the impact our technology has on patients’ lives, and having experienced the passion and dedication of our employees, I could not be more honored, or more confident in our future.”

Blaine Bowman further added, “We unanimously approved the appointment of Francis as President and CEO, and wholeheartedly believe that in their new roles the combination of Jay and Francis will provide the management structure needed to further scale Illumina to address the large, growing genomics market and continue to deliver shareholder value.”

Note to editors: For photos and more information on Francis deSouza, as well as facts and stats about Jay Flatley’s contribution as CEO, please visit: www.illumina.com/company/news-center.html.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding financial statement consolidation and earnings-per-share dilution. Important factors that could cause actual results to differ materially from those in forward-looking statements include the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, and the other factors detailed in Illumina’s filings with the Securities and Exchange Commission, including its most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina assumes no obligation to update any forward-looking statements after the date of this release.

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
IR@illumina.com
or
Media:
Eric Endicott
858-255-5645
PR@illumina.com

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
IR@illumina.com
or
Media:
Eric Endicott
858-255-5645
PR@illumina.com